Additionally, miR-142 targets ASH1L/KMT2H in leukemia and thyroid cancer, miR-675 regulates SUV39H2/KMT1B in liver cancer, miR-122 influences SUV39H1/KMT1A in hepatocellular carcinoma, and miR-101 modulates KMT6/EZH2 in non-small cell lung cancer (NSCLC), prostate, and renal cancers. This evidence concerns the gene ASH1L and hepatocellular carcinoma.